PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)
Year: 2016
Type: article
Source: Annals of Oncology
Institutions: The University of Texas at San Antonio Health Science Center, National Center for Tumor Diseases, Mayo Clinic in Arizona, Baxalta (United States), Indiana University Health, Joliet Oncology-Hematology Associates, Maryland Oncology Hematology, Germantown Historical Society, Albert Einstein College of Medicine, Montefiore Medical Center, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2462818702